bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables 1-3, Supplementary Figure 1, and supplementary references from The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA
Authors: Riviere Paul , Fanta Paul T. , Ikeda Sadakatsu , Baumgartner Joel , Heestand Gregory M. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1: Genes comprising liquid DNA sequencing panel; Supplemental Table 2: Examples of gene alterations and potential targeted therapies; Supplemental Table 3: Correlation between alterations as detected by tissue or liquid biopsy; Figure S1: Bar plot of less-commonly altered genes
Supplementary Information from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Figure legends for supplementary Figures
Supplementary Figure S6. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Pharmacokinetic determination of ICEC0942 plasma and tumor concentrations at different doses and over time.
Supplementary Figure S2. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Analysis of ICEC0942 treatment of MCF7 cells.
Figure S1 and antibody sequence from Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction
Authors: Li Fu , Ulrich Michelle L. , Shih Vincent Feng-Sheng , Cochran Julia H. , Hunter Joshua H. , Westendorf Lori , Neale Jason , Benjamin Dennis R.
Published: April 2023

Additional PK measurements and antibody sequences
Supplementary Figure S1. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

In vitro kinase assays demonstrate selectivity of ICEC0942 for CDK7.
Tables S1 and S2 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma
Authors: Feingold Paul L. , Surman Deborah R. , Brown Kate , Xu Yuan , McDuffie Lucas A. , Shukla Vivek , Reardon Emily S. , Crooks Daniel R. , Trepel Jane B. , Lee Sunmin , Lee Min-Jung , Gao Shaojian , Xi Sichuan , McLoughlin Kaitlin C. , Diggs Laurence P. , Beer David G. , Nancarrow Derek J. , Neckers Leonard M. , Davis Jeremy L. , Hoang Chuong D. , Hernandez Jonathan M. , Schrump David S. , Ripley R. Taylor
Published: April 2023

Cells and Reagents
Supplementary Figure S6 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

SPRY2 is not phosphorylated on tyrosine residues in response to 1 treatment in cells co-expressing V5-SPRY2 and HA-SOS1 S1178A. 293 cells were transiently transfected with both V5-SPRY2 and HA-SOS1 S1178A and treated with 25 μM 1 over a timecourse of up to 90 minutes. Where indicated, cells were treated with FBS (20% v/v) for 15 minutes. Two biological repeats of this experiment were independently conducted.
Table S4 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma
Authors: Feingold Paul L. , Surman Deborah R. , Brown Kate , Xu Yuan , McDuffie Lucas A. , Shukla Vivek , Reardon Emily S. , Crooks Daniel R. , Trepel Jane B. , Lee Sunmin , Lee Min-Jung , Gao Shaojian , Xi Sichuan , McLoughlin Kaitlin C. , Diggs Laurence P. , Beer David G. , Nancarrow Derek J. , Neckers Leonard M. , Davis Jeremy L. , Hoang Chuong D. , Hernandez Jonathan M. , Schrump David S. , Ripley R. Taylor
Published: April 2023

RNAseq Esc2 TXNIP
Supplementary Figure S4 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

Modulation of phospho ERK levels is observed at various treatment concentrations of 1. HeLa cells were treated with between 6.25 μM to 100 μM 1 for a time course of up to 30 minutes. Two biological repeats of this experiment were independently conducted.
Supplementary Figure S2 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

Treatment with 1 causes modulation of RAS-GTP and phospho ERK levels in cell lines expressing mutant RAS isoforms. NCI-H1299, NCI-H358, HCT 116 and NCI-H1792 cells were treated with either 25 μM or 50 μM 1 over a time course of up to 180 minutes. EGF (50 ng/mL for 5 minutes) was used as a positive control. Two biological repeats of each experiment were independently conducted.
Supplementary Figure S1 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

Treatment with 1 does not cause total protein levels of SPRY2, SPRY4, DUSP4 and DUSP16 to increase. HeLa cells were treated with 50 μM 1 over a time course of up to 180 minutes. EGF (50 ng/mL for 5 minutes) was used as a positive control. HCT 116 lysate was included as a positive control for DUSP4 protein levels. Two biological repeats of this experiment were independently conducted.
Supplementary Information from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Authors: Kizilbash Sani H. , Gupta Shiv K. , Chang Kenneth , Kawashima Ryo , Parrish Karen E. , Carlson Brett L. , Bakken Katrina K. , Mladek Ann C. , Schroeder Mark A. , Decker Paul A. , Kitange Gaspar J. , Shen Yuqiao , Feng Ying , Protter Andrew A. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

Supplementary methods and Captions to the Supplementary Figures
Figure S4 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Authors: Kizilbash Sani H. , Gupta Shiv K. , Chang Kenneth , Kawashima Ryo , Parrish Karen E. , Carlson Brett L. , Bakken Katrina K. , Mladek Ann C. , Schroeder Mark A. , Decker Paul A. , Kitange Gaspar J. , Shen Yuqiao , Feng Ying , Protter Andrew A. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

TAL mediated potentiation of TMZ induced G2/M arrest.
Supplemental Methods from Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Lai Holden W.H. , Leiske Christopher I. , Emmerton Kim K. , Waight Andrew B. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

Description of stability experiment, rat tolerability, and chemistry experimentals.
Table S2 from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

Panobinostat levels following IP and IV administration. Six h after injection of PAN 10 mg/kg IP or IV, plasma and selected organs were removed and PAN concentrations determined using HPLC.
Figure S2 from Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Lai Holden W.H. , Leiske Christopher I. , Emmerton Kim K. , Waight Andrew B. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

ADC in vivo stability
Figure S1 from Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Lai Holden W.H. , Leiske Christopher I. , Emmerton Kim K. , Waight Andrew B. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

Free drug stability in cell media
Supplementary methods from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

Supplementary methods.
Figure S3 from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

Radiosensitising effects of panobinostat under hypoxia. A) Effect of 24-hour 25 nM PAN or DMSO on radiosensitivity of RT112 cells under 2% O2 (hypoxia) and normoxia and exposure to irradiation under the same conditions. Normoxia data taken from (14).
Figure S2 from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

Treating mice vertically head-down in the SARRP. Preliminary experiments on freshly dead mice, irradiated then immediately subjected to autopsy, demonstrated that small bowel is at a safe distance from the field edge.
Supplementary Figure 4 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

Additional data from ASTX669 in vivo xenograft studies
Supplementary Figure Legends from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

XIAP antagonism in A375 cells in the presence or absence of TNF-α
Figure S6 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

IHC staining of bladder PDX tumor tissues (BL0293)
Supplementary_Table2 from Pharmacologic Inhibition of the Menin–MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma
Authors: Kempinska Katarzyna , Malik Bhavna , Borkin Dmitry , Klossowski Szymon , Shukla Shirish , Miao Hongzhi , Wang Jingya , Cierpicki Tomasz , Grembecka Jolanta
Published: April 2023

RNA-seq data
Figure S4 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

Blood counts, Hemoglobin and Platelets determination and biochemistry panel
Figure S2 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

Effects of Celecoxib and t-AUCB in PDX BL0269
Figure S6 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S6 shows the efficacy of huA33-BsAb in gastric cancer model
Figure S6 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Heatmap for Cluster 3.
Figure S5 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Protein-protein interaction (A) and pathway analysis (B) for sites exhibiting rapid increase, then decrease (Cluster 5).
Figure S5 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S5 shows the results of affinity maturation of huA33-BsAb
Figure S4 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S4 shows the result of CD45RO and CD25 staining using cells from TDCC assay
Figure S3 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Characterization of NT157-induced SFK activation.
Figure S2 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S2 shows the expression of PD1 on T cells after huA33-BsAb stimulation, as well as the activation of T by huA33-BsAb in the presence of LS174 tumor cells
Figure S1 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S1 shows the expression of GPA33 on colon caner and different healthy tissues
Figure S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Heatmap for Cluster 4.
Table S3 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Pathways to which the identified 24 genes downregulated by JQ1 treatment in CCA2 (Figure 5) contribute.
Table S2 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Gene products downregulated greater than or equal to 2.4-fold by JQ1 in CCA1 tumors.
Table S1 from Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer
Authors: Sunakawa Yu , Mogushi Kaoru , Lenz Heinz-Josef , Zhang Wu , Tsuji Akihito , Takahashi Takehiro , Denda Tadamichi , Shimada Ken , Kochi Mitsugu , Nakamura Masato , Kotaka Masahito , Segawa Yoshihiko , Tanioka Hiroaki , Negoro Yuji , Moran Miriana , Astrow Stephanie H. , Hsiang Jack , Stephens Craig , Fujii Masashi , Ichikawa Wataru
Published: April 2023

Patients' characteristics of JACCRO CC-05/06 and 05/06AR trials
Figure S3 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Immunohistochemistry analysis and nuclear expression indices of BRD4 in first generation (F1) CCA3, CCA4 and CCA5.
Supplementary Figures S1-S8 and Material and Methods from Targeted Delivery of STAT-3 Modulator to Breast Cancer Stem-Like Cells Downregulates a Series of Stemness Genes
Authors: Misra Santosh K. , De Arun , Pan Dipanjan
Published: April 2023

Figure S1. Protocol of CD44 peptide conjugation on NIC-Veh nanoparticles; Figure S2. Physico-chemical properties of NIC-Veh; Figure S3. Bright field images of breast cancer cells (A-C) MDA-MB231 and (D-F) MCF-7 cells without treatment (A, B) or with treatment of (B, E) niclosamide and (C, F) CD44-NIC-Veh for 48h at 20 μM of niclosamide concentration; Figure S4. Flow assisted cell scanning histograms and cell growth analysis post treatment in MCF-7 and MDA-MB231 cells; Figure S5. Histograms of (A) MDA-MB231 cells stained with propidium iodide and after being treated with (B) Nano-Veh; (C) Nic; (D) Nic-Veh and (E) CD44-Nic-Veh; Figure S6. H&E performed on tumor cross sections from animals treated with (A, B) NIC-Veh and (C, D) CD44-NIC-Veh; Figure S7. Immuno-histochemistry performed on tumor cross sections from animals treated with (A, B) CD44-NIC-Veh and (C, D) NIC-Veh; Figure S8. Expression of 'stem-ness genes' namely CD44, CD24, PROM1, LIN28A, LIN28B, ALDH1A1, POU5F1, NOTCH1, SOX2, CTGF, MMP1, EPCAM, FGFR1, ERBB2, CXCR4, PROCR, TGFB1, CTNNB1, WNT1 and WNT2 studied in control tumors and tumors treated with CD44-NIC-Veh.
Figure S2 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

EGFR and c-Myc proteins are overexpressed to similar levels in F0 and corresponding F1 tumors.
Supplementary Table 3 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary Table 3: EPHA2 expression in tumor samples with HSCORE
Supplementary Materials and Methods from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary materials and methods
Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Authors: Cho Song , Zammarchi Francesca , Williams David G. , Havenith Carin E.G. , Monks Noel R. , Tyrer Peter , D'Hooge Francois , Fleming Ryan , Vashisht Kapil , Dimasi Nazzareno , Bertelli Francois , Corbett Simon , Adams Lauren , Reinert Halla W. , Dissanayake Sandamali , Britten Charles E. , King Wanda , Dacosta Karma , Tammali Ravinder , Schifferli Kevin , Strout Patrick , Korade Martin , Masson Hinrichs Mary Jane , Chivers Simon , Corey Eva , Liu He , Kim Sae , Bander Neil H. , Howard Philip W. , Hartley John A. , Coats Steve , Tice David A. , Herbst Ronald , van Berkel Patrick H.
Published: April 2023

Table S1. P values of comparing time to endpoint survival among all treatment groups in the LNCaP xenograft study Table S2. Summary of PSMA IHC in xenograft tumors Table S3. P values of comparing time to endpoint survival among all treatment groups in the CWR22Rv1 xenograft study Table S4. P values of comparing time to endpoint survival among all treatment groups in PC-3 xenograft study
Supplementary Figure 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary Figure 2. A-B: Synergistic anti-proliferative effects of the combination of ALW-II-41-27 and cetuximab.C: Effect of Epha2 gene knockdown on cetuximab sensitivity in HCT116 and LOVO cell lines. D: Effects of combination treatment with ALW-II-41-27 and cetuximab on induction of apoptosis. E: Cell cycle distribution for HCT15 and SW48-CR following treatment with ALW-II-41-27 and/or cetuximab for 24, 48 and 72 hrs at indicated doses. F: Effects of EPHA2 blockade alone and in combination with cetuximab on intracellular signalling pathways of cell proliferation and survival.
Supplementary Figures S1-S7 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Authors: Cho Song , Zammarchi Francesca , Williams David G. , Havenith Carin E.G. , Monks Noel R. , Tyrer Peter , D'Hooge Francois , Fleming Ryan , Vashisht Kapil , Dimasi Nazzareno , Bertelli Francois , Corbett Simon , Adams Lauren , Reinert Halla W. , Dissanayake Sandamali , Britten Charles E. , King Wanda , Dacosta Karma , Tammali Ravinder , Schifferli Kevin , Strout Patrick , Korade Martin , Masson Hinrichs Mary Jane , Chivers Simon , Corey Eva , Liu He , Kim Sae , Bander Neil H. , Howard Philip W. , Hartley John A. , Coats Steve , Tice David A. , Herbst Ronald , van Berkel Patrick H.
Published: April 2023

Supplementary Figure S1. Retention of MEDI3726 activity in human, cynomolgus monkey plasma or PBS for up to 7 days. Supplementary Figure S2. Kaplan-Meier analysis of the Time-to-Endpoint Survival in the (A) LNCaP, (B) CWR22Rv1, and (C) PC-3 Xenograft Studies. Supplementary Figure S3. In Vivo Activity of Isotype Control in CWR22Rv1 the Xenograft Model. Supplementary Figure S4. Cytotoxicity of the Warheads and Their Associated ADCs. Supplementary Figure S5. gamma-H2AX IHC Results. Supplementary Figure S6. Body weight measurements from a representative cell line xenograft and a LuCaP PDX in vivo activity studies. Supplementary Figure S7. Hematology Parameters (Males) following MEDI3726 Administration at 0 (control) & 0.6 mg/kg.
Supplementary Data from Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells
Authors: Plebanek Michael P. , Bhaumik Debayan , Bryce Paul J. , Thaxton C. Shad
Published: April 2023

Supplementary Figures S1-15 and Supplementary Tables S1-S2. Supplementary Figure S1: Flow cytometry gating scheme for SCARB1 expression. S2: Flow cytometry gating scheme for HDL NP targeting of CD11b+ cells. S3: HDL NP cytotoxicity toward CD11b+ cells. S4: Flow cytometry gating scheme for T cells and MDSCs. S5: HDL NP effect on MDSC distribution in lymph nodes. S6: HDL NPs inhibit MDSC-mediated suppression of T cell proliferation. S7: HDL NP toxicity toward MDSCs. S8: HDL NP toxicity toward B16F10 melanoma cells. S9: Survival results from mice with orthotopic implantation of B16F10 melanoma. S10: H&E staining of lungs with B16F10 metastases obtained from SCARB1 -/- mice. S11: SCARB1 expression in CD11b+ bone marrow cells after bone marrow transplant with SCARB1 -/- cells. S12: H&E staining of lungs from mice with established metastases at the time of treatment initiation. S13: F4/80 and CD3 staining of lungs from mice with established metastases at the time of treatment initiation. S14: HDL NP toxicity toward LLC cells. S15: Summary of HDL NP mechanisms of reducing MDSC function. Supplementary Table S1: Table of antibodies used in this study. S2: Table of PCR primers used in this study.
Supplementary Table S3 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Table S3 shows the ratio of AUC0-inf low/high dose for the PK single dose study.
Supplementary Data from EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors
Authors: Chen Kenneth S. , Fustino Nicholas J. , Shukla Abhay A. , Stroup Emily K. , Budhipramono Albert , Ateek Christina , Stuart Sarai H. , Yamaguchi Kiyoshi , Kapur Payal , Frazier A. Lindsay , Lum Lawrence , Looijenga Leendert H.J. , Laetsch Theodore W. , Rakheja Dinesh , Amatruda James F.
Published: April 2023

Supplementary Table 1. Combined immunohistochemistry scores, yolk sac tumor and seminoma Supplementary Table 2. Immunohistochemistry scores for all tumors Supplementary Table 3. Sequences of primers used for quantitative RT-PCR Supplementary Figure 1. Complete blots of NCCIT and NTERA-2 cells treated with ligands. See Figure 4A for more details. Supplementary Figure 2. Complete blots of cells treated with rapamycin. See Figure 5 for more details. Supplementary Figure 3. Complete blots of NCCIT and NTERA-2 cells treated with erlotinib. See Figure 5 for more details. Supplementary Figure 4. Effect of EGFR and mTORC1 inhibitors on the viability of NCCIT cells. Supplementary Figure 5. Model depicting signaling pathways inhibited by erlotinib and rapamycin in NSGCTs
Supplementary Materials and Methods from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary material and methods
Supplementary Tables S1-S4 from The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer
Authors: Forsythe Nicholas , Refaat Alaa , Javadi Arman , Khawaja Hajrah , Weir Jessica-Anne , Emam Heba , Allen Wendy L. , Burkamp Frank , Popovici Vlad , Jithesh Puthen V. , Isella Claudio , Labonte Melissa J. , Mills Ian G. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Table S1: Top 20 pathways identified by IPA containing genes significantly upregulated between poor and good prognostic BRAFMT stage II/III CRC in GSE39582; Table S2: Top 20 pathways identified by IPA containing genes significantly downregulated between poor and good prognostic BRAFMT stage II/III CRC in GSE39582; Table S3: Top 20 pathways identified by IPA containing genes differentially expressed between poor (disease free survival <5 years) and good prognostic BRAFMT stage II CRC (disease free survival >5 years) in E-MTAB-863 and E-MTAB-864; Table S4: Results of siRNA screen in BRAFMT CRC.
Supplemental Table 1 from Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines
Authors: Verduzco Daniel , Kuenzi Brent M. , Kinose Fumi , Sondak Vernon K. , Eroglu Zeynep , Rix Uwe , Smalley Keiran S.M.
Published: April 2023

This file contains the raw data from the drug screen
Supplementary Table S1 from p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Authors: Guan Jiyu , Huang Dan , Yakimchuk Konstantin , Okret Sam
Published: April 2023

Supplementary Table S1 showing QPCR primers used in the study
Supplementary Figures S1-S8 from p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Authors: Guan Jiyu , Huang Dan , Yakimchuk Konstantin , Okret Sam
Published: April 2023

Fig S1: Ibrutinib induces apoptosis and inhibits proliferation of Mino and Rec-1 cells but the effect is impaired by stromal cells. Fig S2: Stromal cells confer ibrutinib resistance by a tumor cell non-autonomous mechanism. Fig S3: Disrupting MCL cell interaction with stromal cells by blocking the adhesion molecule VLA4 overcomes ibrutinib resistance in vitro. Fig S4: Attachment to stromal cells supports MCL cell regrowth after ibrutinib removal. Fig S5: Stromal cells do not influence ibrutinib-mediated down-regulation of NF-κB target genes but impair ibrutinib-mediated down-regulation of pAKT signaling. Fig S6: p110α inhibition overcomes stromal cell-mediated ibrutinib resistance by restoring the ability of ibrutinib to down-regulate pAKT levels. Fig S7: Effects of ibrutinib or BYL719 on mice weight and expression of NF-kB target genes in the MCL tumors. Fig S8: p110α inhibitor BYL719 or ibrutinib do not induce MS-5 stromal cell apoptosis.
Supplementary Materials and Methods; Tables S1-S4; Figures S1-S2 from Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Authors: Ai Jing , Chen Yi , Peng Xia , Ji Yinchun , Xi Yong , Shen Yanyan , Yang Xinying , Su Yi , Sun Yiming , Gao Yinglei , Ma Yuchi , Xiong Bing , Shen Jingkang , Ding Jian , Geng Meiyu
Published: April 2023

Table S1. Enzymatic activities of Compounds against human c-Met; Table S2. Profiling of SCC244 against 313 kinases in Eurofins; Table S3. Anti-proliferative activity of SCC244 on c-Met-addicted cell lines; Table S4. High efficiency of SCC244 in c-Met-dependent cancer cell line derived xenograft models; Figure S1. (A-D) SCC244 was well- tolerated in MKN-45(A&D), SNU-5(B), and EBC-1(C) xenograft models; Figure S2. Intratumoral c-Met expression in 4 NSCLC PDX model with MET aberration detected by immunoblotting prior to the treatment.
Supplementary Figures 1-12 from Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma
Authors: Yu Haiyang , Qiu Yuling , Pang Xu , Li Jian , Wu Song , Yin Shuangshuang , Han Lifeng , Zhang Yi , Jin Chengyun , Gao Xiumei , Hu Wenwei , Wang Tao
Published: April 2023

Supplementary Figure 1. Lycorine has no apparent effect on body weight in nude mice; Supplementary Figure 2. Lycorine induces apoptosis via caspase-dependent pathway; Supplementary Figure 3. Lycorine induces autophagy in HuH-7 cells; Supplementary Figure 4. Inhibition of autophagy promotes the apoptotic effect of lycorine; Supplementary Figure 5. Lycorine promotes apoptosis and autophagy through repressing the Akt/mTOR pathway; Supplementary Figure 6. Lycorine promotes apoptosis and autophagy via TCRP1 pathway in HuH-7 cells; Supplementary Figure 7. The relevance between Akt and TCRP1 in HCC patient tissues; Supplementary Figure 8. Full scans of western-blot data shown in Figure 2; Supplementary Figure 9. Full scans of western-blot data shown in Figure 3; Supplementary Figure 10. Full scans of western-blot data shown in Figure 4; Supplementary Figure 11. Full scans of western-blot data shown in Figure 5; Supplementary Figure 12. Full scans of western-blot data shown in Figure 6.
Supplementary Table 2 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Table S2 is about the pathological features of a panel of human TNBC cell lines
Figure legends from Death by HDAC Inhibition in Synovial Sarcoma Cells
Authors: Laporte Aimée N. , Poulin Neal M. , Barrott Jared J. , Wang Xiu Qing , Lorzadeh Alireza , Vander Werff Ryan , Jones Kevin B. , Underhill T. Michael , Nielsen Torsten O.
Published: April 2023

Figure legends
Supplementary Figure 5 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Fig. S5 is about the effect of Zt/g4-MMAE on tumor weight and number.
Supplementary Figure 1 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Fig. S1 is about the HIC analysis of Zt/g4-MMAE and its stability in PBS
Figure S1, Table S1, Table S2, Supplementary Methods from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
Authors: Osborn Maire F. , Coles Andrew H. , Golebiowski Diane , Echeverria Dimas , Moazami Michael P. , Watts Jonathan K. , Sena-Esteves Miguel , Khvorova Anastasia
Published: April 2023

Figure S1. Cytotoxicity of Chol-hsiRNAs in vitro Table S1. Tumor-associated luciferase activity Table S2. Chol-hsiRNA sequences and chemical modification patterns
Supplementary file containing supplementary Table 1, 2, 3 and Supplementary Figure 1a,1b,1c and 1d. from Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers
Authors: Toor Omer M. , Ahmed Zaheer , Bahaj Waled , Boda Urooge , Cummings Lee S. , McNally Megan E. , Kennedy Kevin F. , Pluard Timothy J. , Hussain Arif , Subramanian Janakiraman , Masood Ashiq
Published: April 2023

Supplementary Table 1. Common genes between Caris, Paradigm and Guardant360 platforms Supplementary Table 2: Common mutations between Guardant 360 and Caris/Paradigm platforms Supplementary Table 3: Actionable mutations detected both in tissue and blood and FDA approved drugs for these mutations Supplementary Figure 1a. Patient with metastatic pancreatic adenocarcinoma to the liver treated with mFOLFIRINOX Supplementary Figure 1b. Patient with metastatic pancreatic adenocarcinoma to liver. Supplementary Figure 1c. Patient with intrahepatic cholangiocarcinoma Supplementary Figure 1d. Patient with adenocarcinoma of lung
Supplementary Figures 1-5 from Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Hancox Ursula , Delpuech Oona , Maynard Juliana , Trigwell Catherine , Eberlein Catherine , Lenaghan Carol , Polanski Radoslaw , Avivar-Valderas Alvaro , Cumberbatch Marie , Klinowska Teresa , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supp Fig 1 Tumour efficacy Supp Fig 2 In vitro gene expression modulation Supp Fig 3 In vivo biomarker analysis Supp Fig 4 HCC70 In vivo FDG uptake imaging Supp Fig 5 U87MG in vivo FDG uptake imaging
Supplementary Methods from Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy
Authors: Dekhne Aamod S. , Shah Khushbu , Ducker Gregory S. , Katinas Jade M. , Wong-Roushar Jennifer , Nayeen Md. Junayed , Doshi Arpit , Ning Changwen , Bao Xun , Frühauf Josephine , Liu Jenney , Wallace-Povirk Adrianne , O'Connor Carrie , Dzinic Sijana H. , White Kathryn , Kushner Juiwanna , Kim Seongho , Hüttemann Maik , Polin Lisa , Rabinowitz Joshua D. , Li Jing , Hou Zhanjun , Dann Charles E. , Gangjee Aleem , Matherly Larry H.
Published: April 2023

Supplementary Method Descriptions Molecular modeling and computational studies Enzyme expression and purification. In vitro enzymatic assays and Ki determinations In vivo efficacy trials with MIA PaCa-2 pancreatic cancer xenografts. Cytochrome c oxidase assay Synthesis of AGF94 and 5-substituted pyrrolo[3,2-d]pyrimidine compounds
Figures S5-S6 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Supplementary Figure 5. Lack of NK cell mediated ADCC and complement protein C1q binding by MEDI6383. Supplementary Figure 6. MEDI6383 mediated release of cytokines from primary human T cells.
Supplementary Table 5 from Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Authors: Shatsky Rebecca , Parker Barbara A. , Bui Nam Q. , Helsten Teresa , Schwab Richard B. , Boles Sarah G , Kurzrock Razelle
Published: April 2023

This table shows examples of studies comparing ctDNA and tissue biopsy genomics
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Supplementary Figure 1. Immunophenotype of CD4 T effector (Teff) and regulatory (Treg) cells used in Teff/Treg co-cultures. ( Supplementary Figure 2. Flow cytometry panels and gating strategy for analysis of rhesus peripheral T cells. Supplementary Figure 3. Binding of MEDI6383 to OX40 expressing human and NHP T cells. Dot plot representing the percentage of purified, live, PHA/IL-2 activated human CD4.
Supplementary Tables S1-S12 from Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
Authors: Lepikhova Tatiana , Karhemo Piia-Riitta , Louhimo Riku , Yadav Bhagwan , Murumägi Astrid , Kulesskiy Evgeny , Kivento Mikko , Sihto Harri , Grénman Reidar , Syrjänen Stina M. , Kallioniemi Olli , Aittokallio Tero , Wennerberg Krister , Joensuu Heikki , Monni Outi
Published: April 2023

Table S1. Genes included in the targeted next-generation sequencing HNSCC gene panel. Table S2. Compounds (n=220) and their drug classes/targets used in the drug screen. Table S3. qPCR primers and qPCR vs GE_microarray correlation. Table S4. Drug sensitivity scores (DSS) of the 220 compounds across 45 UT-SCC HNSCC cell lines. Table S5. All coding mutations found in 45 UT-SCC HNSCC cell lines by targeted sequencing of 694 genes. Table S6. Copy number alterations (CNA) found in 45 UT-SCC HNSCC cell lines. Table S7. Association between mutations and DSS. Table S8. Significant CNA-Drug associations. Table S9. Genes whose amplification is associated with concomitant overexpression. Table S10. Genes whose deletion is associated with concomitant underexpression. Table S11. Significant CNA_gene expression_DSS integration results. Table S12. Gene signatures associated with response to mTOR, MEK and EGFR inhibitors.
Supplementary methods from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
Authors: Grandal Michael M. , Havrylov Serhiy , Poulsen Thomas T. , Koefoed Klaus , Dahlman Anna , Galler Gunther R. , Conrotto Paolo , Collins Sara , Eriksen Karsten W. , Kaufman Dafna , Woude George F.Vande , Jacobsen Helle J. , Horak Ivan D. , Kragh Michael , Lantto Johan , Bouquin Thomas , Park Morag , Pedersen Mikkel W.
Published: April 2023

Supplementary methods
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
Authors: Visintin Alberto , Knowlton Kelly , Tyminski Edyta , Lin Chi-Iou , Zheng Xiang , Marquette Kimberly , Jain Sadhana , Tchistiakova Lioudmila , Li Dan , O'Donnell Christopher J. , Maderna Andreas , Cao Xianjun , Dunn Robert , Snyder William B. , Abraham Anson K. , Leal Mauricio , Shetty Shoba , Barry Anthony , Zawel Leigh , Coyle Anthony J. , Dvorak Harold F. , Jaminet Shou-Ching
Published: April 2023

Supplementary Figures S1-S6. Supplementary Figure S1. Liquid chromatography electrospray ionization tandem mass spectrometry analysis; Supplementary Figure S2. TM4SF1 expression in human breast and colon cancers; Supplementary Figure S3A. Clearance of anti-TM4SF1 antibody from HUVEC surface; Supplementary Figure S3B. Uptake of anti-TM4SF1 antibody in HUVEC; Supplementary Figure S4A. NSCLC killing by anti-TM4SF1 ADC; Supplementary Figure S4B. Tumor cell killing by anti-TM4SF1 ADC; Supplementary Figure S5. Expression level of TM4SF1 and other endothelial cell markers in tumor xenografts; Supplementary Figure S6. Clearance of anti-TM4SF1 ADCs; tolerance in mice.
Supplementary materials from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Legends of Supplementary Figures S1-S7; Supplementary Tables S1-S7
Supplementary Figure S6 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Dose-response effects of mitochondria-targeted doxorubicin on drug-resistant osteosarcoma in vivo
Figure S2 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

MTS assay and clonogenic
Supplementary Figure S5 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Immunohistochemical analysis of drug-resistant osteosarcoma treated with mitochondria-targeted doxorubicin
Figure S1 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

Experimental Plan